Filtered By:
Drug: Botox

This page shows you your search results in order of date.

Order by Relevance | Date

Total 134 results found since Jan 2013.

Botulinum toxin use in patients with post-stroke spasticity: a nationwide retrospective study from France
ConclusionOur analysis of the exhaustive PMSI database showed a suboptimal implementation of BoNT-A treatment recommendations in France. BoNT-A treatment initiation and re-administration are low, particularly in patients with post-stroke spasticity. Further investigations may help explain this observation, and may target specific actions to improve spasticity-related care pathway.
Source: Frontiers in Neurology - August 23, 2023 Category: Neurology Source Type: research

Early versus late injections of Botulinumtoxin type A in post-stroke spastic movement disorder: A literature review
Toxicon. 2023 May 3:107150. doi: 10.1016/j.toxicon.2023.107150. Online ahead of print.ABSTRACTPost-stroke spastic movement disorder (PS-SMD) is one of the main causes of severe disability in the chronic phase after stroke. The prevalence of SMD rises up with time after stroke to more than 28% in the chronic phase, and its secondary complications such as contracture, abnormal postures and/or movement patterns, spasticity-associated pain, also increases with time after stroke when physical and medical management of PS-SMD had been delayed in the early stroke phase. It has been published by several controlled studies that the...
Source: Toxicon - May 5, 2023 Category: Toxicology Authors: J örg Wissel Songjin Ri Anatol Kivi Source Type: research

Po-01-167 efficacy of botulinum toxin type a (agn-151607) for the prevention of postoperative atrial fibrillation in cardiac surgery patients: atrial fibrillation and anticoagulation results from the phase 2 nova study
Oral anticoagulation reduces the risk of stroke but also increases the risk of bleeding. Prevention of post-operative atrial fibrillation (POAF) could result in a lower burden of oral anticoagulation and bleeding events. AGN-151607 has been proposed to prevent POAF and its safety/efficacy was tested in a multicenter randomized trial.
Source: Heart Rhythm - May 1, 2023 Category: Cardiology Authors: Nathan Waldron, Alexandra OSullivan, Jonathan P. Piccini, Matthew Romano, Pierre Voisine, Wilson Titanji, Richard Leaback, William Ferguson, Jonathan S. Steinberg Source Type: research

Clinical efficacy of botulinum toxin type A in patients with traumatic brain injury, spinal cord injury, or multiple sclerosis: An observational longitudinal study
This study aims to clarify the role of BoNT-A in the context of non-stroke spasticity (NSS). We enrolled 86 patients affected by multiple sclerosis, spinal cord injury, and traumatic brain injury with clinical indication to perform BoNT-A treatment. Subjects were evaluated before injection and after 1, 3, and 6 months. At every visit, spasticity severity using the modified Ashworth scale, pain using the numeric rating scale, QoL using the Euro Qol Group EQ-5D-5L, and the perceived treatment effect using the Global Assessment of Efficacy scale were recorded. In our population BoNT-A demonstrated to have a significant effect...
Source: Frontiers in Neurology - April 6, 2023 Category: Neurology Source Type: research

Safety and efficacy of MT10107 in post-stroke upper limb spasticity treatment: A phase I randomized controlled trial
Conclusion: The safety and efficacy of MT10107 showed no significant difference compared to onabotulinumtoxinA in post-stroke upper limb spasticity treatment.
Source: Medicine - November 4, 2022 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Clinical Onset of Action of Incobotulinum Toxin A Preparation
CONCLUSION: This study demonstratedthe onset of IncobotulinumtoxinA efficacy started after 7 days; this rapid action and efficacy of BoNT/A preparation could improve an intensive rehabilitation program after some days post injection. Early clinical onset of action could be by the absence of complexing proteins in the preparation.PMID:35786195 | DOI:10.2174/1871527321666220630154404
Source: CNS and Neurological Disorders Drug Targets - July 5, 2022 Category: Drugs & Pharmacology Authors: Riccardo Marvulli Maurizio Ranieri Laura Belinda Rizzo Francesco Marra Giancar Lo Ianieri Marisa Megna Source Type: research

Botulinum Toxin Use for Modulating Neuroimmune Cutaneous Activity in Psoriasis
Medicina (Kaunas). 2022 Jun 16;58(6):813. doi: 10.3390/medicina58060813.ABSTRACTPsoriasis is a complex immune-mediated inflammatory disorder that generates enormous interest within the scientific communities worldwide, with new therapeutic targets being constantly identified and tested. Despite the numerous topical and systemic medications available for the treatment of psoriasis, alternative therapies are still needed for the optimal management of some patients who present with localized, resistant lesions. Novel insights into the contribution of cutaneous neurogenic inflammation in the pathogenesis of psoriasis have yiel...
Source: Medicina (Kaunas) - June 24, 2022 Category: Universities & Medical Training Authors: Marius Nicolae Popescu Cristina Beiu M ădălina Gabriela Iliescu Mara M ădălina Mihai Liliana Gabriela Popa Ana Maria Alexandra St ănescu Mihai Berteanu Source Type: research